221 related articles for article (PubMed ID: 22673317)
21. Paraoxonase 1 gene polymorphisms, paraoxonase/arylesterase activities and oxidized low-density lipoprotein levels in patients with migraine.
Yıldırım S; Akar S; Kuyucu M; Yıldırım A; Dane S; Aygül R
Cell Biochem Funct; 2011 Oct; 29(7):549-54. PubMed ID: 21755523
[TBL] [Abstract][Full Text] [Related]
22. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects.
Aslan M; Nazligul Y; Horoz M; Bolukbas C; Bolukbas FF; Gur M; Celik H; Erel O
Atherosclerosis; 2008 Jan; 196(1):270-274. PubMed ID: 17125774
[TBL] [Abstract][Full Text] [Related]
23. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
[TBL] [Abstract][Full Text] [Related]
24. Arylesterase activity and antioxidant status depend on PON1-Q192R and PON1-L55M polymorphisms in subjects with increased risk of cardiovascular disease consuming walnut-enriched meat.
Nus M; Frances F; Librelotto J; Canales A; Corella D; Sánchez-Montero JM; Sánchez-Muniz FJ
J Nutr; 2007 Jul; 137(7):1783-8. PubMed ID: 17585031
[TBL] [Abstract][Full Text] [Related]
25. Low-density lipoprotein (LDL)-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies to oxidized-LDL in chronic renal failure patients on dialysis therapy.
O'Byrne D; Devaraj S; Islam KN; Collazo R; McDonald L; Grundy S; Jialal I
Metabolism; 2001 Feb; 50(2):207-15. PubMed ID: 11229431
[TBL] [Abstract][Full Text] [Related]
26. Assessment of paraoxonase activity and lipid peroxidation levels in diabetic and senile subjects suffering from cataract.
Hashim Z; Zarina S
Clin Biochem; 2007 Jun; 40(9-10):705-9. PubMed ID: 17466963
[TBL] [Abstract][Full Text] [Related]
27. Circulating oxidized low density lipoprotein, autoantibodies against them and homocysteine serum levels in diagnosis and estimation of severity of coronary artery disease.
Faviou E; Vourli G; Nounopoulos C; Zachari A; Dionyssiou-Asteriou A
Free Radic Res; 2005 Apr; 39(4):419-29. PubMed ID: 16028367
[TBL] [Abstract][Full Text] [Related]
28. Paraoxonase 1 arylesterase activity and mass are reduced and inversely related to C-reactive protein in patients on either standard or home nocturnal hemodialysis.
Kannampuzha J; Darling PB; Maguire GF; Donnelly S; McFarlane P; Chan CT; Connelly PW
Clin Nephrol; 2010 Feb; 73(2):131-8. PubMed ID: 20129020
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
[TBL] [Abstract][Full Text] [Related]
30. Main determinants of PON1 activity in hemodialysis patients.
Ribeiro S; do Sameiro Faria M; Mascarenhas-Melo F; Freitas I; Mendonça MI; Nascimento H; Rocha-Pereira P; Miranda V; Mendonça D; Quintanilha A; Belo L; Costa E; Reis F; Santos-Silva A
Am J Nephrol; 2012; 36(4):317-23. PubMed ID: 23007074
[TBL] [Abstract][Full Text] [Related]
31. Serum paraoxonase and arylesterase activities in hemodialysis patients.
Itahara T; Suehiro T; Ikeda Y; Inoue M; Nakamura T; Kumon Y; Kawada M; Hashimoto K
J Atheroscler Thromb; 2000; 7(3):152-8. PubMed ID: 11480456
[TBL] [Abstract][Full Text] [Related]
32. Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease.
Samouilidou E; Kostopoulos V; Liaouri A; Kioussi E; Vassiliou K; Bountou E; Grapsa E
Ren Fail; 2016 Nov; 38(10):1601-1606. PubMed ID: 26888625
[TBL] [Abstract][Full Text] [Related]
33. Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease.
Sztanek F; Seres I; Harangi M; Lőcsey L; Padra J; Paragh GJ; Asztalos L; Paragh G
Nephrol Dial Transplant; 2012 Jul; 27(7):2866-72. PubMed ID: 22247228
[TBL] [Abstract][Full Text] [Related]
34. Serum paraoxonase-1 activity in children: the effects of obesity and insulin resistance.
Agirbasli M; Tanrikulu A; Erkus E; Azizy M; Sevim BA; Kaya Z; Taskin A; Aksoy N; Demirbag R
Acta Cardiol; 2014 Dec; 69(6):679-85. PubMed ID: 25643439
[TBL] [Abstract][Full Text] [Related]
35. Relationship between serum paraoxonase and homocysteine thiolactonase activity, adipokines, and asymmetric dimethyl arginine concentrations in renal transplant patients.
Locsey L; Seres I; Sztanek F; Harangi M; Padra J; Kovacs D; Fedor R; Asztalos L; Paragh G
Transplant Proc; 2013; 45(10):3685-7. PubMed ID: 24314997
[TBL] [Abstract][Full Text] [Related]
36. Plasma paraoxonase-1, oxidized low-density lipoprotein and lipid peroxidation levels in gout patients.
Jiang XL; Li M; Zhou JG; Yang QB; Du LJ; Du J
Cell Biochem Biophys; 2011 Nov; 61(2):461-6. PubMed ID: 21748243
[TBL] [Abstract][Full Text] [Related]
37. Is there a relationship between serum ox-LDL, oxidative stress, and PON1 in knee osteoarthritis?
Ertürk C; Altay MA; Bilge A; Çelik H
Clin Rheumatol; 2017 Dec; 36(12):2775-2780. PubMed ID: 28631083
[TBL] [Abstract][Full Text] [Related]
38. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease.
Atamer A; Kocyigit Y; Ecder SA; Selek S; Ilhan N; Ecder T; Atamer Y
J Nephrol; 2008; 21(6):924-30. PubMed ID: 19034878
[TBL] [Abstract][Full Text] [Related]
39. Human plasma paraoxonase 1 (PON1) arylesterase activity during aging: correlation with susceptibility of LDL oxidation.
Mehdi MM; Rizvi SI
Arch Med Res; 2012 Aug; 43(6):438-43. PubMed ID: 22959975
[TBL] [Abstract][Full Text] [Related]
40. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population.
Elkiran ET; Mar N; Aygen B; Gursu F; Karaoglu A; Koca S
BMC Cancer; 2007 Mar; 7():48. PubMed ID: 17362500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
